Indian high commissioner to Nigeria, Abhay Thakur pronounces that his country will be “very happy” to supply its COVID-19 vaccine to Nigeria after it is rolled out inside the next seven days.
He divulged this information during the commemoration of the 16th Pravasi Bhartiya Divas convention, which as well known as the Indian diaspora day, held in Abuja on Saturday.
The high commissioner mentioned that the supply of COVID-19 vaccine doses to Nigeria could be an “important area of collaboration” between the two nations.
“We will be rolling out next week as the vaccines are already announced. So, we will be quite keen to apply for the necessary registration with the regulatory authorities of Nigeria,” NAN quoted him to have said.
“And we will be very happy to supply, on either concessional terms, or any other needs that may be projected by the government of Nigeria.
“In fact, we will like to go out and engage the external world, particularly because we have performed well not only during the COVID period, but in earlier pandemics and contributions to anti-AIDS drugs for Africa.
“We will be ready to collaborate when the registration process, as may be required, is completed, and I am sure this will be an important area of collaboration between our two countries.
“We will have to discuss this with the government of Nigeria. Let it be registered first, and we will have to get the approval process.”
On January 3, Narendra Modi, India’s prime minister, broadcasted the approval of two COVID-19 vaccines developed by Serum Institute and Bharat Biotech.
“A decisive turning point to strengthen a spirited fight! DCGI granting approval to vaccines of @SerumInstIndia and @BharatBiotech accelerates the road to a healthier and COVID-free nation. Congratulations India. Congratulations to our hardworking scientists and innovators,” he had posted in a tweet.
Notwithstanding, few scientists had, expressed concern about the “rushed” approval of the vaccines, particularly Covaxin, produced by Bharat Biotech — the phase 3 trial test results were reported to have not been received at the time of authorization.
Vineeta Bal, an immunologist at India’s National Institute of Immunology, had defined the approval of a vaccine without phase 3 data as “unconscionable”.
However, during a media conference, V.G. Somani, drugs controller-general of India, said although testing had not been concluded on Covaxin, he was approving it as an “abundant precaution”.
Somani said both vaccines were developed for restricted use only, and that the manufacturers would advance with clinical trials.